Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results
Authors
Keywords
-
Journal
NATURE MEDICINE
Volume 29, Issue 9, Pages 2325-2333
Publisher
Springer Science and Business Media LLC
Online
2023-09-01
DOI
10.1038/s41591-023-02517-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
- (2023) Hung Fu Tseng et al. Nature Communications
- Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, December 2022–January 2023
- (2023) Ruth Link-Gelles et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant
- (2023) Daichi Yamasoba et al. LANCET INFECTIOUS DISEASES
- Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial
- (2023) Ivan T Lee et al. LANCET INFECTIOUS DISEASES
- SARS-CoV-2 Omicron boosting induces de novo B cell response in humans
- (2023) Wafaa B. Alsoussi et al. NATURE
- SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination
- (2022) Rolando Pajon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
- (2022) Peter B. Gilbert et al. SCIENCE
- In Elimination Settings, Measles Antibodies Wane After Vaccination but Not After Infection: A Systematic Review and Meta-Analysis
- (2022) Shelly Bolotin et al. JOURNAL OF INFECTIOUS DISEASES
- Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial
- (2022) Laurence Chu et al. NATURE MEDICINE
- Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial
- (2022) Dean Follmann et al. ANNALS OF INTERNAL MEDICINE
- BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
- (2022) Yunlong Cao et al. NATURE
- Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice
- (2022) Suzanne M. Scheaffer et al. NATURE MEDICINE
- A Bivalent Omicron-Containing Booster Vaccine against Covid-19
- (2022) Spyros Chalkias et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neutralization of Omicron Subvariant BA.2.75 after Bivalent Vaccination
- (2022) Spyros Chalkias et al. NEW ENGLAND JOURNAL OF MEDICINE
- Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies
- (2022) Isabel Bergeri et al. PLOS MEDICINE
- Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022
- (2022) Mark W. Tenforde et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years — IVY Network, 18 States, September 8–November 30, 2022
- (2022) Diya Surie et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
- (2021) David S. Khoury et al. NATURE MEDICINE
- Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
- (2021) Hana M. El Sahly et al. NEW ENGLAND JOURNAL OF MEDICINE
- Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants
- (2021) Amarendra Pegu et al. SCIENCE
- Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge
- (2021) Lindsey R. Baden et al. NEW ENGLAND JOURNAL OF MEDICINE
- The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection
- (2020) Paul Kellam et al. JOURNAL OF GENERAL VIROLOGY
- An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
- (2020) Lisa A. Jackson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
- (2020) Lindsey R. Baden et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now